重新认识胰腺癌手术治疗从解剖学向生物学的转变。 - Suppr

Suppr

超能文献

REDISCOVER the change in surgical management of pancreatic cancer from anatomy to biology.

作者信息

Ventin Marco, Ferrone Cristina R

机构信息

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Updates Surg. 2024 Sep;76(5):1569-1571. doi: 10.1007/s13304-024-01956-7. Epub 2024 Aug 16.

DOI:10.1007/s13304-024-01956-7

PMID:39150628

Abstract

摘要

相似文献

REDISCOVER the change in surgical management of pancreatic cancer from anatomy to biology.重新认识胰腺癌手术治疗从解剖学向生物学的转变。

Updates Surg. 2024 Sep;76(5):1569-1571. doi: 10.1007/s13304-024-01956-7. Epub 2024 Aug 16.

REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives.重新发现边界可切除和局部进展期胰腺癌的指南：管理算法、未解决的问题和未来展望。

Updates Surg. 2024 Sep;76(5):1573-1591. doi: 10.1007/s13304-024-01860-0. Epub 2024 Apr 29.

REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer.重新发现关于伴可切除和局部进展期胰腺癌手术患者围手术期护理的国际指南。

Ann Surg. 2024 Jul 1;280(1):56-65. doi: 10.1097/SLA.0000000000006248. Epub 2024 Feb 26.

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.可切除、交界可切除和局部进展期胰腺癌新辅助治疗的意见和应用：国际调查和病例简述研究。

BMC Cancer. 2019 Jul 9;19(1):675. doi: 10.1186/s12885-019-5889-5.

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot.对比影像学 CT 扫描报告在符合国际共识指南的标准下，对胰腺腺癌进行手术可切除性评估：维多利亚州的一项试点研究。

ANZ J Surg. 2022 Oct;92(10):2565-2570. doi: 10.1111/ans.17999. Epub 2022 Aug 24.

A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma.一种以患者为中心的多学科方法治疗边缘可切除性胰腺腺癌。

Chin Clin Oncol. 2022 Dec;11(6):45. doi: 10.21037/cco-22-86. Epub 2022 Nov 29.

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.局部进展期胰腺导管腺癌可切除性判断的共识——Conko-007 多中心试验结果。

BMC Cancer. 2019 Oct 22;19(1):979. doi: 10.1186/s12885-019-6148-5.

Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.局部进展期和可切除边界胰腺癌 FOLFIRINOX 治疗后的手术：CT 上肿瘤衰减增加与 R0 切除相关。

Eur Radiol. 2018 Oct;28(10):4265-4273. doi: 10.1007/s00330-018-5410-6. Epub 2018 Apr 20.

Advances in the Surgical Management of Resectable and Borderline Resectable Pancreas Cancer.可切除及边界可切除胰腺癌手术治疗的进展

Surg Oncol Clin N Am. 2016 Apr;25(2):287-310. doi: 10.1016/j.soc.2015.11.008. Epub 2016 Feb 17.

High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.高分辨率胰腺 CT 评估胰腺导管腺癌可切除性：一项多中心前瞻性研究。

Eur Radiol. 2023 Sep;33(9):5965-5975. doi: 10.1007/s00330-023-09584-2. Epub 2023 Mar 29.

引用本文的文献

Real-World Evidence of Porto-Mesenteric Vein Resections with Pancreatectomy and the Development of Predictive Clinical Nomograms for Postoperative Outcomes-An Analysis of 389 Cases: The "Porto-Mesenteric Vein Resection-Indian MulticentrE" (PRIME) Study.胰十二指肠切除术联合门静脉-肠系膜上静脉切除的真实世界证据及术后结局预测临床列线图的开发——389例分析：“门静脉-肠系膜上静脉切除-印度多中心”（PRIME）研究

Ann Surg Oncol. 2025 Jul 5. doi: 10.1245/s10434-025-17702-1.

本文引用的文献

Correction: Intraperitoneal prophylactic drain after pancreaticoduodenectomy: an Italian survey.更正：胰十二指肠切除术后腹腔预防性引流：一项意大利的调查。

Updates Surg. 2024 Oct;76(6):2501. doi: 10.1007/s13304-024-01967-4.

Ann Surg. 2024 Jul 1;280(1):56-65. doi: 10.1097/SLA.0000000000006248. Epub 2024 Feb 26.

Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2).交界性和局部进展期胰腺癌的切除率和意向治疗结果：一项基于人群、前瞻性队列研究（NORPACT-2）的真实世界数据。

BJS Open. 2023 Nov 1;7(6). doi: 10.1093/bjsopen/zrad137.

Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas.CA125 是可切除胰头胰腺癌的独立预后标志物。

Updates Surg. 2023 Sep;75(6):1481-1496. doi: 10.1007/s13304-023-01587-4. Epub 2023 Aug 3.

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效：A021501 期随机临床试验。

JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.

Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift.可切除胰腺癌的新辅助治疗：不断演变的模式转变

Front Oncol. 2019 Oct 17;9:1085. doi: 10.3389/fonc.2019.01085. eCollection 2019.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.FOLFIRINOX 新辅助治疗联合个体化放化疗治疗边界可切除胰腺腺癌：一项 2 期临床试验。

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.FOLFIRINOX新辅助治疗对局部晚期和边界可切除胰腺癌的放射学及外科意义

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验